Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity. - Yu X; Liao H; Lv J; Sun Y; Zhang R; Chen Y; Lin Y; Liu L; Li S; Tang H; Jia P; Shao B; et al. (Signal transduction and targeted therapy, 2026)